122 related articles for article (PubMed ID: 30656545)
1. Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group.
Keeping S; Deslandes PN; Haines KE; Routledge PA
Pharmacoecon Open; 2019 Sep; 3(3):343-350. PubMed ID: 30656545
[TBL] [Abstract][Full Text] [Related]
2. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
3. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
4. The All Wales Medicines Strategy Group: 18 years' experience of a national medicines optimisation committee.
Haines K; Bracchi R; Lang R; Samuels K; Routledge PA
Br J Clin Pharmacol; 2021 Oct; 87(10):3961-3970. PubMed ID: 33713469
[TBL] [Abstract][Full Text] [Related]
5. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
Linley WG; Hughes DA
Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
[TBL] [Abstract][Full Text] [Related]
6. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
7. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
8. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
10. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
11. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
12. Drug assessment: UK style.
Drug Ther Bull; 2013 Dec; 51(12):141-4. PubMed ID: 24336496
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
14. Public spending on orphan medicines: a review of the literature.
Gombocz M; Vogler S
J Pharm Policy Pract; 2020; 13():66. PubMed ID: 33062285
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting the uptake of new medicines in secondary care - a literature review.
Chauhan D; Mason A
J Clin Pharm Ther; 2008 Aug; 33(4):339-48. PubMed ID: 18613851
[TBL] [Abstract][Full Text] [Related]
16. Financial costs associated with monopolies on biologic medicines in Australia.
Gleeson D; Townsend B; Lopert R; Lexchin J; Moir H
Aust Health Rev; 2019 Feb; 43(1):36-42. PubMed ID: 29116927
[TBL] [Abstract][Full Text] [Related]
17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
[TBL] [Abstract][Full Text] [Related]
18. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
